Wockhardt shares surged after the company received CDSCO approval for its breakthrough antibiotic Zaynich in India. Strong Phase 3 trial results and the drug’s potential to treat severe drug-resistant infections boosted investor sentiment, helping the stock extend recent gains despite technically entering overbought territory after a sharp rally.
Earnings Economic Times May 29, 2026